Retrospective Analysis of U.S. Claims Data Shows AUVI-Q® (epinephrine injection, USP) Prescription Associated with Lower Rates of Anaphylaxis-Related Inpatient Hospitalizations Compared to Other Epinephrine Auto-Injectors

by | May 15, 2025 7:10 pm | Economics

Richmond, Virginia, May 15, 2025 (GLOBE NEWSWIRE) — New findings from a retrospective analysis of U.S. commercial claims data indicate that patients prescribed AUVI-Q® (epinephrine injection, USP) experienced lower rates of inpatient hospitalization for anaphylaxis compared to patients prescribed other epinephrine auto-injectors (EAIs). The results are being presented during the ISPOR 2025 North America Conference, May 13–16, 2025, in Montreal, Quebec, Canada.

“AUVI-Q was designed to guide patients and caregivers through the administration of epinephrine in an allergic emergency,” said Rachael Griffiths, Director, Medical Affairs at Kaléo and study co-author. “These real-world data highlight that AUVI-Q may help patients by reducing the need for hospitalization after anaphylaxis.”

The study, conducted by researchers from ZRx Outcomes Research and Kaléo, evaluated data between January 1 and December 31, 2023. The analysis included 10,130 patients prescribed AUVI-Q and 52,094 patients prescribed other EAIs. Patients in the AUVI-Q cohort were generally younger (mean age 18.9 years vs. 28.5 years) and a greater proportion were male (52% vs. 45.7%) compared to the Other EAI cohort.

Key results include:

  • Anaphylaxis-related inpatient hospitalizations occurred at a rate of 39 per 100,000 patients in the AUVI-Q cohort versus 52 per 100,000 patients in the Other EAI cohort, reflecting a 23.81% relative rate reduction.
  • When measured per anaphylaxis event, the hospitalization rate was 0.00153 for AUVI-Q and 0.00367 for Other EAIs, representing a 58.24% relative reduction.
  • Utilization rates were comparable between groups, with a slightly higher rate observed among AUVI-Q patients (1.316 vs. 1.256).

The study was presented as a poster titled “AUVI-Q (epinephrine, USP) vs. Other Epinephrine Auto-Injector Prescription Was Associated with Reduced Inpatient Hospitalizations for Anaphylaxis in a US Retrospective Commercial Claims Analysis” Wednesday, May 14th during the ISPOR 2025 poster sessions.

###

Indication
AUVI-Q® (epinephrine injection, USP) is a prescription medicine used to treat allergic reactions, including anaphylaxis, …

Full story available on Benzinga.com